BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38501576)

  • 21. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
    Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
    Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
    Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
    Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.
    Roh E; Han Y; Reddy K; Zykova TA; Lee MH; Yao K; Bai R; Curiel-Lewandrowski C; Dong Z
    Oncogene; 2020 May; 39(21):4170-4182. PubMed ID: 32277233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.
    Nandi A; Tidwell M; Karp J; Rapoport AP
    Blood Cells Mol Dis; 2004; 32(1):240-5. PubMed ID: 14757441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.
    Chai Y; Xue H; Wu Y; Du X; Zhang Z; Zhang Y; Zhang L; Zhang S; Zhang Z; Xue Z
    Exp Ther Med; 2018 Jun; 15(6):4822-4828. PubMed ID: 29805502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
    Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
    Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
    Diao X; Yang D; Chen Y; Liu W
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC.
    Hinzman CP; Aljehane L; Brown-Clay JD; Kallakury B; Sonahara F; Goel A; Trevino J; Banerjee PP
    Carcinogenesis; 2018 Dec; 39(12):1548-1559. PubMed ID: 30165468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma.
    Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Anticancer Res; 2016 Dec; 36(12):6457-6466. PubMed ID: 27919968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PBK/TOPK: A Therapeutic Target Worthy of Attention.
    Han Z; Li L; Huang Y; Zhao H; Luo Y
    Cells; 2021 Feb; 10(2):. PubMed ID: 33670114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.
    Wang H; Yang J; Pan H; Tai MC; Maher MH; Jia R; Ge S; Lu L
    Onco Targets Ther; 2020; 13():3903-3920. PubMed ID: 32440155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
    Immunobiology; 2014 Jun; 219(6):469-74. PubMed ID: 24629784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase.
    Zou J; Kuang W; Hu J; Rao H
    Biochem Biophys Res Commun; 2017 Jun; 488(2):247-252. PubMed ID: 28373071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase (PBK/TOPK) in Patients with Cancer.
    Zhang Y; Yang X; Wang R; Zhang X
    J Cancer; 2019; 10(1):131-137. PubMed ID: 30662533
    [No Abstract]   [Full Text] [Related]  

  • 36. Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis.
    Qiao L; Ba J; Xie J; Zhu R; Wan Y; Zhang M; Jin Z; Guo Z; Yu J; Chen S; Yao Y
    World J Surg Oncol; 2022 Sep; 20(1):316. PubMed ID: 36171591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production.
    Uhl C; Nyirenda T; Siegel DS; Lee WY; Zilberberg J
    Heliyon; 2022 Mar; 8(3):e09167. PubMed ID: 35846441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PBK/TOPK Expression Predicts Prognosis in Oral Cancer.
    Chang CF; Chen SL; Sung WW; Hsieh MJ; Hsu HT; Chen LH; Chen MK; Ko JL; Chen CJ; Chou MC
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
    Brown-Clay JD; Shenoy DN; Timofeeva O; Kallakury BV; Nandi AK; Banerjee PP
    Oncotarget; 2015 Jun; 6(17):15594-609. PubMed ID: 25909225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.